REFERENCES
1
1. Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal
tumours. Nat Rev Dis Primers. Mar 18 2021;7(1):22.
2. Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal
tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann. Surg. Oncol. 2018;29(Suppl
4):iv267.
3. Eisenberg BL, Judson I. Surgery and imatinib in the management of
GIST: emerging approaches to adjuvant and neoadjuvant therapy.Ann. Surg. Oncol. 2004;11(5):465-475.
4. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib
mesylate after resection of localised, primary gastrointestinal stromal
tumour: a randomised, double-blind, placebo-controlled trial.Lancet. 2009;373(9669):1097-1104.
5. Corless CL, Ballman KV, Antonescu CR, et al. Pathologic and molecular
features correlate with long-term outcome after adjuvant therapy of
resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin
Oncol. 2014;32(15):1563-1570.
6. Guérin A, Sasane M, Keir CH, et al. Physician Underestimation of the
Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.JAMA oncol. 2015;1(6):797-805.
7. Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant Imatinib for
High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. J Clin
Oncol. 2016;34(3):244-250.
8. Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA
Mutations on Survival in Patients With Gastrointestinal Stromal Tumors
Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized
Clinical Trial. JAMA oncol. 2017;3(5):602-609.
9. Raut CP, Espat NJ, Maki RG, et al. Efficacy and Tolerability of
5-Year Adjuvant Imatinib Treatment for Patients With Resected
Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The
PERSIST-5 Clinical Trial. JAMA oncol. 2018;4(12):e184060.
10. Joensuu H, Eriksson M, Sundby Hall K, et al. Survival Outcomes
Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With
High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized
Clinical Trial After 10-Year Follow-up. JAMA oncol.2020;6(8):1241-1246.
11. Cavnar MJ, Seier K, Curtin C, et al. Outcome of 1000 Patients With
Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and
Post-imatinib Eras. Ann Surg. 2021;273(1):128-138.
12. Vincenzi B, Napolitano A, Fiocco M, et al. Adjuvant Imatinib in
Patients with GIST Harboring Exon 9 KIT Mutations: Results from a
Multi-institutional European Retrospective Study. Clin Cancer
Res. 2021.
13. Xu S-J, Zhang S-Y, Dong L-Y, Lin G-S, Zhou Y-J. Dynamic survival
analysis of gastrointestinal stromal tumors (GISTs): a 10-year follow-up
based on conditional survival. BMC cancer. 2021;21(1):1170.
14. Zhang Q, Xu J, Qian Y, et al. Association of Imatinib Plasma
Concentration and Single-nucleotide Polymorphisms with Adverse Drug
Reactions in Patients with Gastrointestinal Stromal Tumors. Mol
Cancer Ther. 2018;17(12):2780-2787.
15. Wu X, Li J, Zhou Y, et al. Relative Factors Analysis of Imatinib
Trough Concentration in Chinese Patients with Gastrointestinal Stromal
Tumor. Chemotherapy. 2018;63(6):301-307.
16. Xia Y, Chen S, Luo M, et al. Correlations between imatinib plasma
trough concentration and adverse reactions in Chinese patients with
gastrointestinal stromal tumors. Cancer. 2020;126 Suppl
9:2054-2061.
17. Ishikawa Y, Kiyoi H, Watanabe K, et al. Trough plasma concentration
of imatinib reflects BCR-ABL kinase inhibitory activity and clinical
response in chronic-phase chronic myeloid leukemia: a report from the
BINGO study. Cancer Sci. 2010;101(10):2186-2192.
18. Yin Y, Xiang J, Tang S, Chen J, Yu Q, Zhang B. A lower dosage of
imatinib in patients with gastrointestinal stromal tumors with toxicity
of the treatment. Medicine (Baltimore). Dec 2016;95(49):e5488.
19. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are
correlated with clinical benefit in patients with
unresectable/metastatic gastrointestinal stromal tumors. J Clin
Oncol. Jul 1 2009;27(19):3141-3147.
20. Bouchet S, Poulette S, Titier K, et al. Relationship between
imatinib trough concentration and outcomes in the treatment of advanced
gastrointestinal stromal tumours in a real-life setting. Eur J
Cancer. Apr 2016;57:31-38.
21. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX.
Pharmacokinetic/pharmacodynamic correlation and blood-level testing in
imatinib therapy for chronic myeloid leukemia. Leukemia.2009;23(9):1537-1544.
22. National Comprehensive Cancer Network. Management of
immunotherapy-related toxicities (Version 1.2020).https://www.
nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Accessed
October 5, 2020.
23. Fornasaro S, Bonifacio A, Marangon E, et al. Label-Free
Quantification of Anticancer Drug Imatinib in Human Plasma with Surface
Enhanced Raman Spectroscopy. Anal Chem. 2018;90(21):12670-12677.
24. Cole SR, Hernan MA. Constructing inverse probability weights for
marginal structural models. Am J Epidemiol. Sep
2008;168(6):656-664.
25. Rajyaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency Ablation
Versus Stereotactic Body Radiotherapy for Localized Hepatocellular
Carcinoma in Nonsurgically Managed Patients: Analysis of the National
Cancer Database. J Clin Oncol. 2018;36(6):600-608.
26. Farag S, Verheijen RB, Martijn Kerst J, Cats A, Huitema ADR, Steeghs
N. Imatinib Pharmacokinetics in a Large Observational Cohort of
Gastrointestinal Stromal Tumour Patients. Clin Pharmacokinet.2017;56(3):287-292.
27. Adiwidjaja J, Gross AS, Boddy AV, McLachlan AJ.
Physiologically-based pharmacokinetic model predictions of inter-ethnic
differences in imatinib pharmacokinetics and dosing regimens. Br J
Clin Pharmacol. 2021:16.
2-27